Clinical Scorecard: Assessment of MEDI0618, a pH-sensitive monoclonal antibody aimed at PAR2, in preclinical migraine models
At a Glance
Category
Detail
Condition
Migraine and post-traumatic headache
Key Mechanisms
Inhibition of protease activated receptor 2 (PAR2) to prevent neuronal sensitization and migraine-like pain
Target Population
Patients with migraine, including those with CGRP-dependent and CGRP-independent attacks
Care Setting
Clinical development for migraine prevention
Key Highlights
MEDI0618 is a fully humanized monoclonal antibody targeting PAR2 with high specificity and affinity.
MEDI0618 effectively prevented migraine-like pain in multiple murine models, including CGRP-independent mechanisms.
MEDI0618 did not show efficacy in a model of post-traumatic headache induced by mild traumatic brain injury.
Guideline-Based Recommendations
Diagnosis
Migraine diagnosis remains clinical; PAR2 involvement suggested by preclinical models.
Consider evaluation of migraine patients non-responsive to CGRP-targeting therapies for alternative mechanisms.
Management
MEDI0618 represents a novel therapeutic approach targeting PAR2 for migraine prevention.
Potential use in patients with breakthrough migraine attacks despite CGRP-targeted therapies.
Not effective for post-traumatic headache based on preclinical data.
Monitoring & Follow-up
Monitor migraine frequency and severity to assess response to PAR2-targeted therapy.
Observe for breakthrough attacks and evaluate for CGRP-independent mechanisms.
Risks
Safety and efficacy in humans under clinical investigation; no adverse effects reported in preclinical models.
Potential lack of efficacy in post-traumatic headache patients.
Patient & Prescribing Data
Patients with migraine, including those unresponsive to CGRP receptor antagonists
MEDI0618 shows efficacy in preventing migraine-like pain induced by various triggers, including mast cell degranulation and inflammatory mediators, but not effective for post-traumatic headache.
Clinical Best Practices
Consider PAR2 blockade as a complementary approach in migraine prevention, especially in CGRP non-responders.
Evaluate patient history for mast cell activation or allergy-related triggers that may implicate PAR2 involvement.
Use subcutaneous administration of MEDI0618 prior to anticipated migraine triggers based on preclinical dosing strategies.
Continue monitoring for breakthrough attacks and adjust therapy accordingly.
by Caroline M Kopruszinski, John E Linley, Peter Thornton, Alison S Walker, Philip Newton, Sadhana Podichetty, Radhey Hemendra Ruparel, Luiz Henrique Moreira de Souza, Edita Navratilova, Guy Meno-Tetang, Ian Gurrell, David W Dodick, Claire Dobson, Tharani Chessell, Frank Porreca, Iain Chessell
